


[CLAIMS]

[Claim 1]

A compound represented by the general formula (I):

[C1]




wherein, R^1 represents 3-oxetanyl, 3,3,3-trifluoropropyl, ethyl or a hydrogen atom; R^2 represents a C1-4 alkyl, a C1-4 alkoxy, a halogen, nitrile or a C1-4 alkoxy carbonyl; R^3 represents a C1-4 alkyl or a hydrogen atom; R^4 represents a hydrogen atom, a C1-4 alkyl, a C5-6 monocyclic carbocycle which may be substituted with 1 to 3 R^7 groups or a 5- to 6-membered monocyclic heterocycle which may be substituted with 1 to 3 R^8 groups; R^7 represents a halogen or a C1-4 alkyl; R^8 represents a halogen or a C1-4 alkyl; when the C5-6 monocyclic carbocycle is substituted with 2 or more R^7 groups, a plurality of R^7 may be the same or different; when the 5- to 6-membered monocyclic heterocycle is substituted with 2 or more R^8 groups, a plurality of R^8 may be the same or different; R^5 represents a C1-4 alkyl or a hydrogen atom; ring1 represents a C5-6 monocyclic carbocycle or a 5- to 6-membered monocyclic heterocycle; R^6 represents a C1-4 alkyl, a C1-4 alkoxy or a halogen; m represents an integer of 0 to 3; n represents an integer of 0 to 3; when m is 2 or more, a plurality of R^2 may

be the same or different; and when n is 2 or more, a plurality of R⁶ may be the same or different,

or a salt thereof (excluding rac-(3R,4S)-4-amino-1-[3-(3,5-dimethoxyphenyl)-5-(4,6-dimethyl-1H-benzimidazol-2-yl)-4-pyridinyl]-3-piperidinol, rac-(3R,4S)-4-amino-1-[3-(6-fluoro-1H-benzimidazol-2-yl)-5-(3-fluoro-5-methoxyphenyl)-4-pyridinyl]-3-piperidinol and rac-(3R,4S)-4-amino-1-[3-(6-chloro-1H-benzimidazol-2-yl)-5-(3-fluoro-5-methoxyphenyl)-4-pyridinyl]-3-piperidinol).

[Claim 2]

The compound according to claim 1, wherein the compound represented by the general formula (I) is a compound represented by the general formula (IB):




wherein R¹⁻¹ represents 3-oxetanyl, 3,3,3-trifluoropropyl or ethyl; and other symbols have the same meanings as described in claim 1,

or a salt thereof.

[Claim 3]

The compound according to claim 1 or 2, wherein the compound represented by the general formula (IB) is a compound represented by the general formula (IB-1):

[C3]



wherein all symbols have the same meanings as described in claim 1 or 2,

5 or a salt thereof.

[Claim 4]

The compound according to any one of claims 1 to 3, wherein R^2 is a C1-4 alkoxy, a halogen or a C1-4 alkoxy carbonyl; and R^6 is a C1-4 alkoxy or a halogen,

10 or a salt thereof.

[Claim 5]

The compound according to any one of claims 1 to 4, wherein R^6 is a halogen; and n is 2, or a salt thereof.

15 [Claim 6]

The compound according to claim 2, wherein the compound is:

(1) (3S,4R)-1-[3-(5,6-difluoro-1H-benzimidazol-2-yl)-5-(3,5-difluorophenyl)-4-pyridinyl]-4-(3-oxetanylamino)-3-

20 piperidinol;

(2) (3S,4R)-1-[3-(3-chloro-5-fluorophenyl)-5-(5,6-difluoro-1H-benzimidazol-2-yl)-4-pyridinyl]-4-[(3,3,3-trifluoropropyl)amino]-3-piperidinol;

(3) (3S,4R)-1-[3-(5,6-difluoro-1H-benzimidazol-2-yl)-5-(2,5-difluorophenyl)-4-pyridinyl]-4-(ethylamino)-3-piperidinol;

(4) (3S,4R)-1-[3-(5,6-difluoro-1H-benzimidazol-2-yl)-5-(3-fluoro-5-methoxyphenyl)-4-pyridinyl]-4-[(3,3,3-

5 trifluoropropyl)amino]-3-piperidinol; or

(5) (3S,4R)-1-[3-(3,5-difluorophenyl)-5-(6-fluoro-5-methoxy-1H-benzimidazol-2-yl)-4-pyridinyl]-4-[(3,3,3-trifluoropropyl)amino]-3-piperidinol,

or a salt thereof.

10 [Claim 7]

The compound according to claim 6, wherein the compound is (3S,4R)-1-[3-(5,6-difluoro-1H-benzimidazol-2-yl)-5-(3,5-difluorophenyl)-4-pyridinyl]-4-(3-oxetanylamino)-3-piperidinol, or a salt thereof.

15


[Claim 8]

The compound according to claim 1, wherein R⁴ is a C1-4 alkyl, a C5-6 monocyclic carbocycle which may be substituted with 1 to 3 R⁷ groups or a 5- to 6-membered monocyclic
20 heterocycle which may be substituted with 1 to 3 R⁸ groups, or a salt thereof.

[Claim 9]

The compound according to claim 8, wherein the compound represented by the general formula (I) is a compound
25 represented by the general formula (I-1):

[C4]



wherein R^{4-1} represents a C1-4 alkyl, a C5-6 monocyclic carbocycle which may be substituted with 1 to 3 R^7 groups or a 5- to 6-membered monocyclic heterocycle which may be substituted with 1 to 3 R^8 groups; and other symbols have the same meanings as described in claim 1, or a salt thereof.

[Claim 10]

The compound according to claim 8 or 9, wherein R^2 is a C1-4 alkoxy, a halogen or a C1-4 alkoxy carbonyl; and R^6 is a C1-4 alkoxy or a halogen, or a salt thereof.

[Claim 11]

The compound according to any one of claims 8 to 10, wherein R^6 is a halogen; and n is 2, or a salt thereof.

[Claim 12]

The compound according to claim 8, wherein the compound is:

- (1) (3S,4R)-4-amino-1-[3-(5,6-difluoro-1H-benzimidazol-2-yl)-5-(3,5-difluorophenyl)-2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]-3-piperidinol;
- (2) methyl 2-{4-[(3S,4R)-4-amino-3-hydroxy-1-piperidinyl]-5-

(3-chloro-5-fluorophenyl)-2-methyl-3-pyridinyl}-5-fluoro-1H-benzimidazole-7-carboxylate;

(3) methyl 2-{4-[(3S,4R)-4-amino-3-hydroxy-1-piperidinyl]-5-(2,5-difluorophenyl)-2-methyl-3-pyridinyl}-5-fluoro-1H-

5 benzimidazole-7-carboxylate;

(4) (3S,4R)-4-amino-1-[5-(3,5-difluorophenyl)-2-methyl-3-(5,6,7-trifluoro-1H-benzimidazol-2-yl)-4-pyridinyl]-3-piperidinol;

(5) (3S,4R)-1-[5-(3-chloro-5-fluorophenyl)-3-(6-methoxy-1H-benzimidazol-2-yl)-2-methyl-4-pyridinyl]-4-(3-oxetanylamino)-3-piperidinol;

(6) (3S,4R)-1-[5-(3,5-difluorophenyl)-3-(5-fluoro-6-methoxy-1H-benzimidazol-2-yl)-2-methyl-4-pyridinyl]-4-(ethylamino)-3-piperidinol;

15 (7) (3S,4R)-1-[5-(3-chloro-5-fluorophenyl)-3-(5,6-difluoro-1H-benzimidazol-2-yl)-2-methyl-4-pyridinyl]-4-(3-oxetanylamino)-3-piperidinol;

(8) (3S,4R)-1-[3-(5,6-difluoro-1H-benzimidazol-2-yl)-5-(3,5-difluorophenyl)-2-methyl-4-pyridinyl]-4-[(3,3,3-

20 trifluoropropyl)amino]-3-piperidinol;

(9) (3S,4R)-1-[5-(3,5-difluorophenyl)-2-methyl-3-(5,6,7-trifluoro-1H-benzimidazol-2-yl)-4-pyridinyl]-4-(ethylamino)-3-piperidinol; or

(10) methyl 2-{4-[(3S,4R)-4-amino-3-hydroxy-1-piperidinyl]-5-(3,5-difluorophenyl)-2-(4-morpholinyl)-3-pyridinyl}-5-fluoro-1H-benzimidazole-7-carboxylate,

or a salt thereof.

[Claim 13]


The compound according to claim 1, wherein R⁴ is a
30 hydrogen atom,
or a salt thereof.

[Claim 14]

The compound according to claim 1 or 13, wherein the compound represented by the general formula (I) is a compound

represented by the general formula (I-2):

[C5]



wherein all symbols have the same meanings as described in

5 claim 1,

or a salt thereof.

[Claim 15]

The compound according to claim 13 or 14, wherein R² is
a C1-4 alkoxy, a halogen or a C1-4 alkoxycarbonyl; and R⁶ is a

10 C1-4 alkoxy or a halogen,

or a salt thereof.

[Claim 16]

The compound according to any one of claims 13 to 15,
wherein R⁶ is a halogen; and n is 2,

15 or a salt thereof.

[Claim 17]

The compound according to claim 13, wherein the compound
is:

(1) (3S,4R)-4-amino-1-[3-(5,6-difluoro-1H-benzimidazol-2-yl)-
20 5-(3,5-difluorophenyl)-4-pyridinyl]-3-piperidinol;

(2) (3S,4R)-4-amino-1-[3-(1H-benzimidazol-2-yl)-5-(3,5-
difluorophenyl)-4-pyridinyl]-3-piperidinol;

(3) (3S,4R)-4-amino-1-[3-(2,5-difluorophenyl)-5-(6-methoxy-1H-

benzimidazol-2-yl)-4-pyridinyl]-3-piperidinol; or

(4) methyl 2-{4-[(3S,4R)-4-amino-3-hydroxy-1-piperidinyl]-5-(2,5-difluorophenyl)-3-pyridinyl}-5-fluoro-1H-benzimidazole-7-carboxylate,

5 or a salt thereof.

[claim 18]

The compound according to claim 17, wherein the compound is
10 (3S,4R)-4-amino-1-[3-(5,6-difluoro-1H-benzimidazol-2-yl)-5-(3,5-difluorophenyl)-4-pyridinyl]-3-piperidinol, or a salt thereof.

[Claim 19]

A pharmaceutical composition comprising the compound
15 represented by the general formula (I) according to claim 1 or a salt thereof, and a pharmaceutically acceptable carrier.

[Claim 20]

The pharmaceutical composition according to claim 19,
which is a somatostatin receptor agonist.

20 [Claim 21]

The pharmaceutical composition according to claim 19 or
20, which is a prophylactic and/or therapeutic agent for a somatostatin-related disease.

[Claim 22]

25 The pharmaceutical composition according to any one of claims 19 to 21, wherein the somatostatin-related disease is acromegaly, or a gastrointestinal symptom accompanying gastrointestinal obstruction.

[Claim 23]

30 A prophylactic and/or therapeutic agent for a somatostatin-related disease, comprising the compound represented by the general formula (I) according to claim 1 or a salt thereof as an active component, wherein the prophylactic and/or therapeutic agent is administered together
35 with at least one drug selected from the group consisting of

pegvisomant, bromocriptine and cabergoline.

[Claim 24]

A prophylactic and/or therapeutic agent comprising the compound represented by the general formula (I) according to claim 1 or a salt thereof as an active component, and at least one drug selected from the group consisting of prochlorperazine, levomepromazine, risperidone, metoclopramide, domperidone, diphenhydramine, chlorpheniramine, dimenhydrinate, promethazine, diprophylline, famotidine, cimetidine, scopolamine, tropisetron, granisetron, ondansetron, azasetron, ramosetron, indisetron, palonosetron, cisapride, mosapride, dexamethasone, betamethasone, prednisolone, aprepitant, olanzapine, quetiapine, perospirone, methylnaltrexone and morphine for use in treating a somatostatin- related disease.

15 [Claim 25]

The compound represented by the general formula (I) according to claim 1 or a salt thereof for use in prophylaxis and/or therapy of a somatostatin-related disease.

[Claim 26]

20 Use of the compound represented by the general formula (I) according to claim 1 or a salt thereof in the manufacture of a prophylactic and/or therapeutic agent for the treatment of asomatostatin-related disease.